Prostatype Genomics AB Logo

Prostatype Genomics AB

Provides a genetic test to assess prostate cancer aggressiveness and guide treatment choices.

PROGEN | ST

Overview

Corporate Details

ISIN(s):
SE0022574554 (+2 more)
LEI:
549300JO6MPCGPVHVU91
Country:
Sweden
Address:
Gustav III:s Boulevard 34, 169 73 Solna
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Prostatype Genomics AB specializes in the development, manufacturing, and marketing of the prognostic genetic test, Prostatype®. The test is designed to provide a comprehensive assessment of the aggressiveness of diagnosed prostate cancer, particularly for patients with localized disease. It serves as a decision-making tool for clinicians and patients to help determine appropriate treatment strategies. The Prostatype® system uses existing biopsy tissue to analyze the expression of three key genes. This genetic data is combined with standard clinical parameters (PSA, Gleason Score, Tumor Stage) to calculate a proprietary P-score, which quantifies the risk of cancer mortality. By offering a more precise prognosis, the test aims to minimize both over- and under-treatment, thereby improving patient quality of life and saving healthcare resources.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Prostatype Genomics AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Prostatype Genomics AB

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Prostatype Genomics AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Ceres Power Holdings PLC Logo
Licensing solid oxide tech (SOFC/SOEC) for clean power and green hydrogen to global partners.
United Kingdom
CWR
Certara, Inc. Logo
Accelerating new medicines with biosimulation software and services for pharma & biotech.
United States of America
CERT
CervoMed Inc. Logo
Developing CNS therapeutics for neurodegenerative diseases like dementia with Lewy bodies.
United States of America
CRVO
Chabiotech Co.,Ltd. Logo
Develops cell/gene therapies and offers CDMO, biobanking, and genomics services for rare diseases.
South Korea
085660
CHAMPIONS ONCOLOGY, INC. Logo
Oncology CRO accelerating drug development with PDX models and multi-omic data analytics.
United States of America
CSBR
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Logo
Global CRO for pharma & biotech, offering research models, safety testing & manufacturing solutions.
United States of America
CRL
Chiome Bioscience Inc. Logo
Clinical-stage biotech developing therapeutic antibodies and providing R&D services to partners.
Japan
4583
Chordate Medical Holding AB Logo
Develops drug-free neuromodulation tech for chronic migraine & rhinitis in the EU & Middle East.
Sweden
CMH
Chordia Therapeutics,Inc Logo
Developing first-in-class, small-molecule anti-cancer drugs targeting RNA deregulation.
Japan
190A
Cibus, Inc. Logo
Develops & licenses gene-edited, non-transgenic traits to the seed industry for resilient crops.
United States of America
CBUS

Talk to a Data Expert

Have a question? We'll get back to you promptly.